Streetbeat News

Price Targets

AKBA

HC Wainwright & Co. analyst Ed Arce reiterated a Neutral rating on Akebia Therapeutics (NASDAQ:AKBA) and maintained a $2 price target.

Portfolio Pulse from richadhand@benzinga.com

June 14, 2023 | 10:22 am

ATRA

HC Wainwright & Co. analyst Robert Burns maintains a Buy rating on Atara Biotherapeutics (NASDAQ:ATRA) and raises the price target from $27 to $28.

Portfolio Pulse from richadhand@benzinga.com

June 14, 2023 | 10:21 am

GMAB

HC Wainwright & Co. analyst Raghuram Selvaraju reiterated a Buy rating on Genmab (NASDAQ:GMAB) and maintained a $51 price target.

Portfolio Pulse from richadhand@benzinga.com

June 14, 2023 | 10:20 am

MRNS

HC Wainwright & Co. analyst Douglas Tsao reiterates a Buy rating on Marinus Pharma (NASDAQ:MRNS) and maintains a $27 price target.

Portfolio Pulse from richadhand@benzinga.com

June 14, 2023 | 10:18 am

ACAD

HC Wainwright & Co. analyst Andrew Fein reiterated a Buy rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) and maintained a $28 price target.

Portfolio Pulse from richadhand@benzinga.com

June 14, 2023 | 10:18 am

ACRS

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Aclaris Therapeutics (NASDAQ:ACRS) and maintained a $43 price target.

Portfolio Pulse from richadhand@benzinga.com

June 14, 2023 | 10:17 am

ZURA

Chardan Capital analyst Matthew Barcus initiates coverage on Zura Bio (NASDAQ:ZURA) with a Buy rating and announces a price target of $14.

Portfolio Pulse from richadhand@benzinga.com

June 14, 2023 | 10:16 am

NOW

Needham analyst Jack Andrews initiates coverage on ServiceNow (NYSE:NOW) with a Buy rating and announces a price target of $660.

Portfolio Pulse from richadhand@benzinga.com

June 14, 2023 | 10:14 am

AMAM

B. Riley Securities analyst Yuan Zhi initiates coverage on Ambrx Biopharma (NASDAQ:AMAM) with a Buy rating and announces a price target of $26.

Portfolio Pulse from richadhand@benzinga.com

June 14, 2023 | 10:13 am

SHAK

Piper Sandler analyst Brian Mullan assumes Shake Shack (NYSE:SHAK) with an Overweight rating and announces a price target of $84.

Portfolio Pulse from richadhand@benzinga.com

June 14, 2023 | 10:10 am